Trials Sponsors Conditions Drugs Pricing

Conditions

Acute Respiratory Distress Syndrome Acute Respiratory Failure Covid19 Post Intensive Care Unit Syndrome Survivorship

Keywords

ICU treatment

Outcome Measures

Primary Outcomes (2)

ICU Survival rate
Time to survival
up to 30 days
Change in Functional Status
Measured by self-reporting using Lawton Instrumental activity of daily living. Higher score indicates better function, and ranges from 0-8.
6 and 12 months after ICU admission

Secondary Outcomes (3)

Change in Anxiety and Depression
Measured 6 and 12 months after ICU admission

Interventions

ICU treatmentOther

This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

All patients that have been admitted to a Norwegian ICU with confirmed COVID-19, and not reserved them against the national register, will be contacted for inclusion to the study.

You may qualify if:

Patients registered in Norwegian Intensive Care Register, that are ≥ 18 years with confirmed cases of COVID-19.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

The Research Council of Norway
Othercollaborator
Oslo University Hospital
Otherlead

Study Sites (1)

Oslo University Hospital

Oslo, 0027, Norway

Related Publications (1)

Laake JH, Hagen M, Aavitsland P, Buanes EA, Fjone KS, Kvale R, Olsen BF, Hofso K. COVID-19 in Norwegian ICUs 2020-2023: Patient characteristics, management, and outcomes-A nationwide prospective observational study. Acta Anaesthesiol Scand. 2025 Apr;69(4):e70027. doi: 10.1111/aas.70027.
PMID: 40114460DERIVED

MeSH Terms

Conditions

COVID-19Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Officials

Kristin Hofsø, PhD
Oslo University Hospital
PRINCIPAL INVESTIGATOR

Enrollment

860 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 1 Year
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: PhD

Study Record Dates

First Submitted

October 15, 2020

First Posted

October 23, 2020

Study Start

September 16, 2020

Actual (reported)

Survival Rates and Longterm Outcomes After COVID-19

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations